Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Macrophages | 43 | 2022 | 191 | 9.600 |
Why?
|
Monocytes | 23 | 2022 | 127 | 7.900 |
Why?
|
Atherosclerosis | 20 | 2022 | 768 | 5.240 |
Why?
|
Glutathione | 16 | 2018 | 43 | 2.560 |
Why?
|
Oxidative Stress | 15 | 2022 | 231 | 2.190 |
Why?
|
Chemotaxis, Leukocyte | 6 | 2019 | 22 | 2.080 |
Why?
|
Lipoproteins, LDL | 16 | 2014 | 81 | 2.060 |
Why?
|
Oxidation-Reduction | 19 | 2022 | 268 | 1.850 |
Why?
|
Glutaredoxins | 6 | 2022 | 9 | 1.820 |
Why?
|
Receptors, LDL | 11 | 2021 | 65 | 1.800 |
Why?
|
Mice | 38 | 2022 | 2485 | 1.800 |
Why?
|
Dual Specificity Phosphatase 1 | 4 | 2018 | 29 | 1.700 |
Why?
|
Chemotaxis | 5 | 2019 | 24 | 1.610 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2017 | 50 | 1.580 |
Why?
|
Macrophages, Peritoneal | 6 | 2016 | 18 | 1.530 |
Why?
|
Animals | 51 | 2022 | 7543 | 1.520 |
Why?
|
Triterpenes | 3 | 2018 | 4 | 1.490 |
Why?
|
Reactive Oxygen Species | 11 | 2022 | 157 | 1.490 |
Why?
|
Positron-Emission Tomography | 3 | 2017 | 163 | 1.470 |
Why?
|
Aortic Diseases | 3 | 2018 | 63 | 1.440 |
Why?
|
Mice, Inbred C57BL | 17 | 2022 | 767 | 1.250 |
Why?
|
Cells, Cultured | 22 | 2016 | 833 | 1.210 |
Why?
|
Sulfhydryl Compounds | 5 | 2021 | 33 | 1.180 |
Why?
|
Signal Transduction | 11 | 2017 | 682 | 1.110 |
Why?
|
Mice, Knockout | 13 | 2021 | 443 | 1.020 |
Why?
|
Aorta | 5 | 2018 | 126 | 1.010 |
Why?
|
Oxygen | 4 | 2013 | 142 | 0.950 |
Why?
|
Obesity | 3 | 2022 | 1176 | 0.890 |
Why?
|
Mitochondria | 4 | 2016 | 187 | 0.820 |
Why?
|
Protective Agents | 1 | 2022 | 4 | 0.820 |
Why?
|
Inflammation | 7 | 2019 | 530 | 0.810 |
Why?
|
Stress, Physiological | 4 | 2017 | 55 | 0.780 |
Why?
|
Cell Adhesion | 5 | 2017 | 108 | 0.770 |
Why?
|
Apoptosis | 8 | 2015 | 360 | 0.710 |
Why?
|
Chemokine CCL2 | 6 | 2019 | 48 | 0.690 |
Why?
|
Disease Models, Animal | 11 | 2018 | 1022 | 0.690 |
Why?
|
Glutathione Reductase | 4 | 2007 | 9 | 0.690 |
Why?
|
Protein Processing, Post-Translational | 2 | 2016 | 78 | 0.660 |
Why?
|
Vitamin E | 4 | 2001 | 23 | 0.650 |
Why?
|
Humans | 46 | 2019 | 32040 | 0.640 |
Why?
|
Mitogen-Activated Protein Kinases | 2 | 2017 | 37 | 0.620 |
Why?
|
Glucose | 2 | 2016 | 174 | 0.620 |
Why?
|
Proteins | 2 | 2016 | 144 | 0.610 |
Why?
|
Dyslipidemias | 1 | 2018 | 53 | 0.600 |
Why?
|
Glutamine | 1 | 2017 | 9 | 0.600 |
Why?
|
Deoxyglucose | 1 | 2017 | 16 | 0.600 |
Why?
|
Macrophage Colony-Stimulating Factor | 1 | 2016 | 5 | 0.570 |
Why?
|
Cell Line | 11 | 2016 | 435 | 0.570 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2016 | 29 | 0.560 |
Why?
|
Diabetes Mellitus, Experimental | 3 | 2011 | 55 | 0.540 |
Why?
|
Cues | 1 | 2016 | 68 | 0.530 |
Why?
|
Doxorubicin | 2 | 2006 | 82 | 0.510 |
Why?
|
Phenotype | 4 | 2019 | 632 | 0.500 |
Why?
|
Leukocytes, Mononuclear | 2 | 2010 | 56 | 0.490 |
Why?
|
14-3-3 Proteins | 1 | 2014 | 4 | 0.480 |
Why?
|
Wound Healing | 4 | 2013 | 185 | 0.480 |
Why?
|
Foam Cells | 5 | 2005 | 13 | 0.470 |
Why?
|
Lipoproteins | 4 | 2006 | 86 | 0.470 |
Why?
|
Female | 16 | 2022 | 19993 | 0.420 |
Why?
|
Lipoproteins, HDL | 3 | 2010 | 251 | 0.400 |
Why?
|
Gold | 4 | 2012 | 18 | 0.390 |
Why?
|
Dinoprostone | 5 | 1994 | 31 | 0.390 |
Why?
|
Platelet Activating Factor | 6 | 1994 | 14 | 0.390 |
Why?
|
Actins | 4 | 2014 | 51 | 0.390 |
Why?
|
Cardiovascular Agents | 1 | 2011 | 23 | 0.380 |
Why?
|
Venae Cavae | 1 | 2010 | 4 | 0.380 |
Why?
|
Graft Occlusion, Vascular | 1 | 2010 | 24 | 0.370 |
Why?
|
Heart Failure | 1 | 2017 | 636 | 0.370 |
Why?
|
Diabetic Angiopathies | 1 | 2011 | 143 | 0.360 |
Why?
|
Male | 19 | 2022 | 19194 | 0.360 |
Why?
|
Cholesterol | 4 | 2005 | 252 | 0.350 |
Why?
|
Extracellular Matrix Proteins | 3 | 2016 | 45 | 0.340 |
Why?
|
Transforming Growth Factor beta | 3 | 2016 | 64 | 0.340 |
Why?
|
Cholesterol Esters | 4 | 2004 | 36 | 0.340 |
Why?
|
Time Factors | 8 | 2014 | 2151 | 0.330 |
Why?
|
Hypercholesterolemia | 1 | 2009 | 69 | 0.320 |
Why?
|
Receptors, Immunologic | 3 | 2005 | 21 | 0.310 |
Why?
|
Hydrogen Peroxide | 4 | 2016 | 83 | 0.300 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2006 | 210 | 0.300 |
Why?
|
Cell Death | 5 | 2010 | 77 | 0.300 |
Why?
|
Cell Differentiation | 6 | 2018 | 469 | 0.300 |
Why?
|
Arteriosclerosis | 4 | 2005 | 123 | 0.290 |
Why?
|
LDL-Receptor Related Proteins | 1 | 2007 | 10 | 0.290 |
Why?
|
Lipid Metabolism | 4 | 2005 | 105 | 0.280 |
Why?
|
Lipopolysaccharides | 8 | 2006 | 109 | 0.280 |
Why?
|
Transfection | 6 | 2014 | 191 | 0.280 |
Why?
|
Kidney Diseases | 1 | 2009 | 249 | 0.270 |
Why?
|
Oxidoreductases | 1 | 2006 | 26 | 0.270 |
Why?
|
Interleukin-10 | 1 | 2006 | 30 | 0.270 |
Why?
|
Interleukin-6 | 2 | 2006 | 247 | 0.260 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2014 | 633 | 0.260 |
Why?
|
Adenoviridae | 3 | 2007 | 66 | 0.260 |
Why?
|
Retina | 2 | 2016 | 61 | 0.250 |
Why?
|
Gene Knockdown Techniques | 2 | 2016 | 77 | 0.250 |
Why?
|
Energy Metabolism | 3 | 2015 | 147 | 0.240 |
Why?
|
Radiopharmaceuticals | 2 | 2016 | 93 | 0.240 |
Why?
|
Caspases | 2 | 2003 | 39 | 0.240 |
Why?
|
Kidney Failure, Chronic | 2 | 2006 | 541 | 0.240 |
Why?
|
Gene Expression Regulation | 3 | 2017 | 495 | 0.230 |
Why?
|
Endothelial Cells | 3 | 2015 | 189 | 0.220 |
Why?
|
Peroxides | 1 | 2003 | 32 | 0.220 |
Why?
|
Tomography, Optical Coherence | 2 | 2014 | 45 | 0.210 |
Why?
|
Phosphorylation | 2 | 2014 | 229 | 0.210 |
Why?
|
Cell Culture Techniques | 2 | 2006 | 173 | 0.210 |
Why?
|
Lipids | 4 | 2012 | 232 | 0.210 |
Why?
|
Metal Nanoparticles | 2 | 2012 | 16 | 0.200 |
Why?
|
Stilbenes | 2 | 2012 | 23 | 0.200 |
Why?
|
Histone Deacetylase 2 | 1 | 2021 | 1 | 0.200 |
Why?
|
Antigens, CD | 2 | 2016 | 103 | 0.190 |
Why?
|
Gene Transfer Techniques | 2 | 2004 | 63 | 0.190 |
Why?
|
Models, Biological | 6 | 2006 | 392 | 0.180 |
Why?
|
Nanoparticles | 2 | 2012 | 52 | 0.180 |
Why?
|
Computational Biology | 2 | 2019 | 91 | 0.170 |
Why?
|
Macrophage Activation | 2 | 2016 | 11 | 0.170 |
Why?
|
Basement Membrane | 1 | 2019 | 8 | 0.170 |
Why?
|
Cell Count | 1 | 2019 | 47 | 0.170 |
Why?
|
Severity of Illness Index | 3 | 2015 | 882 | 0.170 |
Why?
|
Extracellular Space | 2 | 2016 | 25 | 0.170 |
Why?
|
Adenosine Triphosphate | 2 | 2019 | 53 | 0.170 |
Why?
|
Metabolomics | 1 | 2019 | 54 | 0.170 |
Why?
|
Genomics | 1 | 2019 | 85 | 0.160 |
Why?
|
Neuroglia | 1 | 2019 | 30 | 0.160 |
Why?
|
Microscopy, Confocal | 2 | 2012 | 65 | 0.160 |
Why?
|
Cell Movement | 2 | 2017 | 169 | 0.160 |
Why?
|
Proteomics | 1 | 2019 | 94 | 0.160 |
Why?
|
Central Nervous System | 1 | 2019 | 43 | 0.160 |
Why?
|
Transforming Growth Factor beta1 | 2 | 2016 | 28 | 0.160 |
Why?
|
Dehydroascorbic Acid | 1 | 1998 | 1 | 0.160 |
Why?
|
Genetic Variation | 1 | 2000 | 244 | 0.160 |
Why?
|
Diet | 1 | 2021 | 391 | 0.160 |
Why?
|
Thiocarbamates | 2 | 2010 | 6 | 0.160 |
Why?
|
Tubulin | 1 | 2018 | 12 | 0.160 |
Why?
|
Neuroblastoma | 1 | 2018 | 31 | 0.150 |
Why?
|
Multiple Sclerosis | 1 | 2019 | 59 | 0.150 |
Why?
|
Spleen | 2 | 2010 | 87 | 0.150 |
Why?
|
Inositol 1,4,5-Trisphosphate | 2 | 1994 | 6 | 0.150 |
Why?
|
Autoradiography | 1 | 2017 | 45 | 0.150 |
Why?
|
Microscopy, Phase-Contrast | 2 | 2015 | 12 | 0.150 |
Why?
|
Weight Gain | 1 | 2018 | 117 | 0.150 |
Why?
|
Dementia, Vascular | 1 | 2017 | 12 | 0.150 |
Why?
|
Chromatography, Thin Layer | 1 | 1997 | 8 | 0.150 |
Why?
|
Up-Regulation | 3 | 2014 | 189 | 0.150 |
Why?
|
Bone Marrow Transplantation | 2 | 2008 | 63 | 0.140 |
Why?
|
Fetus | 1 | 2017 | 86 | 0.140 |
Why?
|
Enzyme Inhibitors | 3 | 2014 | 166 | 0.140 |
Why?
|
Transforming Growth Factor beta2 | 1 | 2016 | 6 | 0.140 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2017 | 92 | 0.140 |
Why?
|
Cerebrovascular Circulation | 1 | 2017 | 93 | 0.140 |
Why?
|
Protein Interaction Mapping | 1 | 2016 | 8 | 0.140 |
Why?
|
Pericytes | 1 | 2016 | 29 | 0.140 |
Why?
|
Triglycerides | 1 | 1997 | 230 | 0.130 |
Why?
|
Staining and Labeling | 1 | 2016 | 60 | 0.130 |
Why?
|
Immunity, Innate | 1 | 2016 | 75 | 0.130 |
Why?
|
Diabetic Retinopathy | 1 | 2016 | 65 | 0.130 |
Why?
|
Refractometry | 1 | 2015 | 1 | 0.130 |
Why?
|
Nephelometry and Turbidimetry | 1 | 2015 | 3 | 0.130 |
Why?
|
Enzyme Activation | 5 | 2005 | 135 | 0.130 |
Why?
|
Blotting, Western | 2 | 2016 | 289 | 0.130 |
Why?
|
Epigenesis, Genetic | 1 | 2016 | 104 | 0.130 |
Why?
|
RNA, Small Interfering | 2 | 2006 | 114 | 0.130 |
Why?
|
Neurons | 1 | 2019 | 410 | 0.130 |
Why?
|
Ethanol | 1 | 2017 | 187 | 0.130 |
Why?
|
Gene Expression | 1 | 2016 | 338 | 0.120 |
Why?
|
Nitric Oxide | 2 | 2006 | 111 | 0.120 |
Why?
|
Cyclic AMP | 1 | 1994 | 46 | 0.120 |
Why?
|
Calcium | 2 | 1994 | 307 | 0.120 |
Why?
|
Actin Depolymerizing Factors | 1 | 2014 | 1 | 0.120 |
Why?
|
Lim Kinases | 1 | 2014 | 1 | 0.120 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2014 | 8 | 0.120 |
Why?
|
Ionomycin | 2 | 1994 | 4 | 0.120 |
Why?
|
Mice, Transgenic | 3 | 2012 | 264 | 0.120 |
Why?
|
Sulfonamides | 1 | 1994 | 67 | 0.120 |
Why?
|
Rats | 3 | 2014 | 1596 | 0.120 |
Why?
|
Hypertension, Pulmonary | 1 | 2014 | 24 | 0.120 |
Why?
|
Pulmonary Artery | 1 | 2014 | 24 | 0.120 |
Why?
|
Dietary Supplements | 2 | 2014 | 185 | 0.120 |
Why?
|
Endothelium, Vascular | 3 | 2012 | 156 | 0.120 |
Why?
|
MAP Kinase Signaling System | 1 | 2014 | 61 | 0.110 |
Why?
|
Cell Polarity | 1 | 2013 | 16 | 0.110 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2013 | 3 | 0.110 |
Why?
|
Hyperbaric Oxygenation | 1 | 2013 | 6 | 0.110 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2014 | 80 | 0.110 |
Why?
|
Mutation | 2 | 2014 | 489 | 0.110 |
Why?
|
Coronary Vessels | 1 | 2014 | 166 | 0.110 |
Why?
|
Toxicity Tests | 1 | 2012 | 13 | 0.110 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2012 | 19 | 0.110 |
Why?
|
Glutathione Transferase | 1 | 2012 | 13 | 0.110 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 35 | 0.110 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 36 | 0.110 |
Why?
|
Quercetin | 1 | 2012 | 8 | 0.100 |
Why?
|
Carotid Artery Injuries | 1 | 2012 | 7 | 0.100 |
Why?
|
Hyperplasia | 1 | 2012 | 41 | 0.100 |
Why?
|
RNA Interference | 1 | 2012 | 76 | 0.100 |
Why?
|
Chemokine CCL5 | 1 | 2011 | 7 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2011 | 9 | 0.100 |
Why?
|
Caspase 3 | 2 | 2003 | 33 | 0.100 |
Why?
|
Adiponectin | 1 | 2012 | 106 | 0.100 |
Why?
|
Antioxidants | 3 | 2012 | 115 | 0.100 |
Why?
|
Iron | 1 | 2012 | 116 | 0.100 |
Why?
|
Receptors, CCR2 | 1 | 2011 | 4 | 0.100 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 94 | 0.100 |
Why?
|
Binding, Competitive | 2 | 2005 | 33 | 0.100 |
Why?
|
Calcimycin | 2 | 1990 | 6 | 0.100 |
Why?
|
Immunoblotting | 2 | 2008 | 51 | 0.090 |
Why?
|
Hyperlipidemias | 1 | 2011 | 54 | 0.090 |
Why?
|
Regional Blood Flow | 1 | 2010 | 86 | 0.090 |
Why?
|
Mice, Inbred Strains | 1 | 2010 | 48 | 0.090 |
Why?
|
Vascular Patency | 1 | 2010 | 69 | 0.090 |
Why?
|
Pyrrolidines | 1 | 2010 | 12 | 0.090 |
Why?
|
Carotid Arteries | 1 | 2010 | 99 | 0.090 |
Why?
|
Wounds and Injuries | 1 | 2013 | 253 | 0.090 |
Why?
|
SRS-A | 1 | 1990 | 1 | 0.090 |
Why?
|
Brain | 1 | 2017 | 951 | 0.090 |
Why?
|
Administration, Topical | 1 | 2010 | 140 | 0.090 |
Why?
|
Administration, Cutaneous | 1 | 2010 | 116 | 0.090 |
Why?
|
Eosinophils | 1 | 1990 | 29 | 0.090 |
Why?
|
Transduction, Genetic | 2 | 2007 | 42 | 0.090 |
Why?
|
Ferric Compounds | 1 | 2009 | 15 | 0.090 |
Why?
|
Culture Media, Serum-Free | 2 | 2000 | 16 | 0.090 |
Why?
|
Streptozocin | 1 | 2009 | 8 | 0.090 |
Why?
|
Blood Chemical Analysis | 1 | 2009 | 22 | 0.080 |
Why?
|
Urinalysis | 1 | 2009 | 27 | 0.080 |
Why?
|
Osteosarcoma | 1 | 2009 | 11 | 0.080 |
Why?
|
Free Radical Scavengers | 2 | 2017 | 14 | 0.080 |
Why?
|
Scavenger Receptors, Class B | 2 | 2006 | 12 | 0.080 |
Why?
|
Sensitivity and Specificity | 3 | 2015 | 596 | 0.080 |
Why?
|
Adipose Tissue | 1 | 2012 | 349 | 0.080 |
Why?
|
Probability | 1 | 2009 | 159 | 0.080 |
Why?
|
Insulin Resistance | 1 | 2012 | 462 | 0.080 |
Why?
|
Models, Chemical | 2 | 2006 | 34 | 0.080 |
Why?
|
Random Allocation | 1 | 2009 | 226 | 0.080 |
Why?
|
Reproducibility of Results | 3 | 2015 | 765 | 0.080 |
Why?
|
Receptors, Scavenger | 3 | 2005 | 7 | 0.080 |
Why?
|
Kininogen, High-Molecular-Weight | 1 | 2008 | 6 | 0.080 |
Why?
|
Amifostine | 1 | 2008 | 2 | 0.080 |
Why?
|
Radiation-Protective Agents | 1 | 2008 | 5 | 0.080 |
Why?
|
Analysis of Variance | 1 | 2009 | 463 | 0.080 |
Why?
|
Transplantation Conditioning | 1 | 2008 | 13 | 0.080 |
Why?
|
Stem Cells | 1 | 2010 | 313 | 0.080 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2016 | 1428 | 0.080 |
Why?
|
Bone Neoplasms | 1 | 2009 | 111 | 0.080 |
Why?
|
Sphingomyelin Phosphodiesterase | 1 | 2007 | 5 | 0.080 |
Why?
|
Apolipoproteins E | 2 | 2005 | 95 | 0.070 |
Why?
|
Genistein | 2 | 2006 | 15 | 0.070 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2007 | 17 | 0.070 |
Why?
|
Cytosol | 1 | 2007 | 25 | 0.070 |
Why?
|
Retroviridae | 1 | 2007 | 28 | 0.070 |
Why?
|
Kidney | 1 | 2011 | 518 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 1 | 2007 | 105 | 0.070 |
Why?
|
Genetic Vectors | 1 | 2007 | 120 | 0.070 |
Why?
|
Soy Foods | 1 | 2006 | 7 | 0.070 |
Why?
|
Graft Rejection | 1 | 2008 | 238 | 0.070 |
Why?
|
Dietary Fats | 1 | 2007 | 110 | 0.070 |
Why?
|
Acute-Phase Proteins | 1 | 2006 | 10 | 0.070 |
Why?
|
Bone Marrow Cells | 1 | 2007 | 123 | 0.070 |
Why?
|
Sepsis | 1 | 2008 | 159 | 0.070 |
Why?
|
Graft Survival | 1 | 2008 | 314 | 0.070 |
Why?
|
Ribosomal Proteins | 1 | 2006 | 4 | 0.070 |
Why?
|
Proline | 1 | 2006 | 12 | 0.070 |
Why?
|
Blood Cell Count | 1 | 2006 | 29 | 0.070 |
Why?
|
Peptide Fragments | 1 | 2009 | 399 | 0.070 |
Why?
|
Rabbits | 3 | 2012 | 197 | 0.070 |
Why?
|
Heat-Shock Proteins | 1 | 2006 | 34 | 0.070 |
Why?
|
Diamide | 1 | 2005 | 3 | 0.070 |
Why?
|
Glutathione Disulfide | 1 | 2005 | 2 | 0.070 |
Why?
|
NF-kappa B | 1 | 2006 | 81 | 0.070 |
Why?
|
Fluoresceins | 1 | 2005 | 8 | 0.070 |
Why?
|
Carmustine | 1 | 2005 | 8 | 0.070 |
Why?
|
Retinal Vessels | 2 | 2016 | 19 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2006 | 82 | 0.070 |
Why?
|
Electrons | 1 | 2005 | 12 | 0.070 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2005 | 40 | 0.060 |
Why?
|
Quinolinium Compounds | 1 | 2005 | 1 | 0.060 |
Why?
|
Cytochalasin D | 1 | 2005 | 4 | 0.060 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2005 | 4 | 0.060 |
Why?
|
RNA, Messenger | 2 | 2017 | 508 | 0.060 |
Why?
|
Myocytes, Cardiac | 1 | 2005 | 86 | 0.060 |
Why?
|
Nitric Oxide Synthase | 1 | 2005 | 35 | 0.060 |
Why?
|
Coloring Agents | 1 | 2005 | 29 | 0.060 |
Why?
|
Lasers | 2 | 2012 | 21 | 0.060 |
Why?
|
Hyperhomocysteinemia | 1 | 2004 | 5 | 0.060 |
Why?
|
Homocysteine | 1 | 2004 | 14 | 0.060 |
Why?
|
Polymers | 1 | 2005 | 64 | 0.060 |
Why?
|
Cell Membrane | 1 | 2005 | 96 | 0.060 |
Why?
|
Scattering, Radiation | 2 | 2015 | 5 | 0.060 |
Why?
|
COS Cells | 2 | 2004 | 27 | 0.060 |
Why?
|
Light | 2 | 2015 | 24 | 0.060 |
Why?
|
Biological Transport | 2 | 2009 | 69 | 0.060 |
Why?
|
Case-Control Studies | 1 | 2006 | 895 | 0.060 |
Why?
|
Renal Dialysis | 1 | 2006 | 279 | 0.050 |
Why?
|
Uncoupling Agents | 1 | 2003 | 1 | 0.050 |
Why?
|
Chromans | 1 | 2003 | 5 | 0.050 |
Why?
|
Cytoprotection | 1 | 2003 | 6 | 0.050 |
Why?
|
Superoxides | 1 | 2003 | 19 | 0.050 |
Why?
|
Oxidants | 1 | 2002 | 14 | 0.050 |
Why?
|
Antibodies | 1 | 2003 | 52 | 0.050 |
Why?
|
Adult | 3 | 2006 | 9358 | 0.050 |
Why?
|
Hydrogen-Ion Concentration | 2 | 2012 | 66 | 0.050 |
Why?
|
Spectrophotometry, Ultraviolet | 2 | 2012 | 18 | 0.050 |
Why?
|
Blood Physiological Phenomena | 1 | 2000 | 1 | 0.050 |
Why?
|
Poly I | 1 | 2000 | 1 | 0.050 |
Why?
|
Thrombospondins | 1 | 2000 | 6 | 0.050 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 2000 | 6 | 0.050 |
Why?
|
Amino Acid Chloromethyl Ketones | 1 | 2000 | 6 | 0.050 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2000 | 14 | 0.050 |
Why?
|
Ceramides | 1 | 2000 | 10 | 0.050 |
Why?
|
Platelet Membrane Glycoproteins | 2 | 1991 | 7 | 0.050 |
Why?
|
Cell Proliferation | 2 | 2014 | 604 | 0.050 |
Why?
|
Leukocytes | 1 | 2001 | 57 | 0.050 |
Why?
|
Culture Media | 1 | 2000 | 47 | 0.050 |
Why?
|
Oligopeptides | 1 | 2000 | 45 | 0.050 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2001 | 63 | 0.050 |
Why?
|
Adjuvants, Immunologic | 1 | 2001 | 55 | 0.050 |
Why?
|
Receptors, Cell Surface | 2 | 1991 | 70 | 0.040 |
Why?
|
DNA, Recombinant | 1 | 2000 | 7 | 0.040 |
Why?
|
Biotechnology | 1 | 2000 | 6 | 0.040 |
Why?
|
Cytological Techniques | 1 | 2000 | 17 | 0.040 |
Why?
|
Receptors, G-Protein-Coupled | 2 | 1991 | 85 | 0.040 |
Why?
|
Plasmids | 1 | 2000 | 48 | 0.040 |
Why?
|
DNA Primers | 1 | 2000 | 91 | 0.040 |
Why?
|
Middle Aged | 3 | 2006 | 11847 | 0.040 |
Why?
|
Cell Division | 1 | 2000 | 99 | 0.040 |
Why?
|
Base Sequence | 1 | 2000 | 252 | 0.040 |
Why?
|
NADP | 1 | 2019 | 9 | 0.040 |
Why?
|
DNA | 1 | 2000 | 226 | 0.040 |
Why?
|
Cell Communication | 1 | 2019 | 32 | 0.040 |
Why?
|
Phagocytosis | 1 | 1998 | 14 | 0.040 |
Why?
|
Alloxan | 1 | 1998 | 1 | 0.040 |
Why?
|
Immunophenotyping | 1 | 1998 | 50 | 0.040 |
Why?
|
Dithiothreitol | 1 | 1998 | 8 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2000 | 246 | 0.040 |
Why?
|
Neuralgia | 1 | 2019 | 48 | 0.040 |
Why?
|
Ascorbic Acid | 1 | 1998 | 23 | 0.040 |
Why?
|
Leukemia P388 | 1 | 1997 | 2 | 0.040 |
Why?
|
Buthionine Sulfoximine | 1 | 2017 | 2 | 0.040 |
Why?
|
Antimetabolites | 1 | 2017 | 11 | 0.040 |
Why?
|
Acetylcysteine | 1 | 2017 | 11 | 0.040 |
Why?
|
Microchemistry | 1 | 1997 | 5 | 0.040 |
Why?
|
Densitometry | 1 | 1997 | 8 | 0.040 |
Why?
|
Amino Acid Sequence | 2 | 2009 | 285 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 153 | 0.040 |
Why?
|
Cyclooxygenase Inhibitors | 2 | 1994 | 40 | 0.040 |
Why?
|
Arterioles | 1 | 2016 | 13 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 2 | 1994 | 40 | 0.040 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 21 | 0.030 |
Why?
|
Disease Progression | 1 | 2019 | 593 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2016 | 198 | 0.030 |
Why?
|
Cytokines | 1 | 2017 | 255 | 0.030 |
Why?
|
Biological Transport, Active | 1 | 1995 | 8 | 0.030 |
Why?
|
Equipment Failure Analysis | 1 | 2015 | 43 | 0.030 |
Why?
|
CHO Cells | 2 | 2006 | 24 | 0.030 |
Why?
|
Cricetinae | 2 | 2006 | 39 | 0.030 |
Why?
|
Equipment Design | 1 | 2015 | 172 | 0.030 |
Why?
|
Isoquinolines | 1 | 1994 | 7 | 0.030 |
Why?
|
Phospholipids | 1 | 1994 | 28 | 0.030 |
Why?
|
Monocrotaline | 1 | 2014 | 2 | 0.030 |
Why?
|
Hypertrophy, Right Ventricular | 1 | 2014 | 6 | 0.030 |
Why?
|
Egtazic Acid | 1 | 1994 | 3 | 0.030 |
Why?
|
Virulence Factors, Bordetella | 1 | 1994 | 9 | 0.030 |
Why?
|
Pertussis Toxin | 1 | 1994 | 17 | 0.030 |
Why?
|
Pregnancy | 1 | 2017 | 996 | 0.030 |
Why?
|
Indoles | 1 | 2014 | 56 | 0.030 |
Why?
|
Pyrroles | 1 | 2014 | 55 | 0.030 |
Why?
|
Phospholipases A | 2 | 1991 | 26 | 0.030 |
Why?
|
Fibroblasts | 1 | 2014 | 111 | 0.030 |
Why?
|
Arachidonic Acids | 2 | 1991 | 23 | 0.030 |
Why?
|
Macaca mulatta | 1 | 2015 | 305 | 0.030 |
Why?
|
Acids | 1 | 2012 | 3 | 0.030 |
Why?
|
Solutions | 1 | 2012 | 36 | 0.030 |
Why?
|
Thromboxane B2 | 1 | 2012 | 6 | 0.030 |
Why?
|
Protein Stability | 1 | 2012 | 25 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 2012 | 78 | 0.030 |
Why?
|
Molecular Weight | 1 | 2012 | 41 | 0.030 |
Why?
|
Drug Interactions | 1 | 2012 | 79 | 0.030 |
Why?
|
Organ Specificity | 1 | 2012 | 81 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2014 | 245 | 0.030 |
Why?
|
Neoplasms | 1 | 2019 | 724 | 0.030 |
Why?
|
Infrared Rays | 1 | 2012 | 18 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 1 | 2014 | 743 | 0.030 |
Why?
|
Microscopy | 1 | 2012 | 26 | 0.030 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2012 | 48 | 0.030 |
Why?
|
Fatty Liver | 1 | 2012 | 66 | 0.020 |
Why?
|
Oxygen Consumption | 1 | 2012 | 154 | 0.020 |
Why?
|
Algorithms | 1 | 2014 | 496 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2014 | 352 | 0.020 |
Why?
|
Phospholipases | 1 | 1990 | 2 | 0.020 |
Why?
|
Nigericin | 1 | 1990 | 2 | 0.020 |
Why?
|
Gamma Rays | 1 | 2010 | 25 | 0.020 |
Why?
|
Buffers | 1 | 1990 | 9 | 0.020 |
Why?
|
Horses | 1 | 1990 | 15 | 0.020 |
Why?
|
Necrosis | 1 | 2010 | 53 | 0.020 |
Why?
|
Isoflavones | 2 | 2006 | 81 | 0.020 |
Why?
|
Spectrophotometry, Infrared | 1 | 2009 | 2 | 0.020 |
Why?
|
Magnetics | 1 | 2009 | 5 | 0.020 |
Why?
|
Surface Properties | 1 | 2009 | 32 | 0.020 |
Why?
|
Particle Size | 1 | 2009 | 46 | 0.020 |
Why?
|
Integrins | 1 | 2009 | 41 | 0.020 |
Why?
|
Protein Binding | 1 | 2009 | 201 | 0.020 |
Why?
|
Blood Coagulation Tests | 1 | 2008 | 7 | 0.020 |
Why?
|
Graft vs Host Disease | 1 | 2008 | 21 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2008 | 151 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2008 | 167 | 0.020 |
Why?
|
Interleukin-1beta | 1 | 2007 | 42 | 0.020 |
Why?
|
Whole-Body Irradiation | 1 | 2008 | 53 | 0.020 |
Why?
|
Kinetics | 2 | 2002 | 209 | 0.020 |
Why?
|
Rats, Inbred F344 | 1 | 2007 | 133 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2009 | 726 | 0.020 |
Why?
|
Prealbumin | 1 | 2006 | 9 | 0.020 |
Why?
|
Dairy Products | 1 | 2006 | 13 | 0.020 |
Why?
|
Beverages | 1 | 2006 | 19 | 0.020 |
Why?
|
Food, Formulated | 1 | 2006 | 12 | 0.020 |
Why?
|
Conserved Sequence | 1 | 2006 | 20 | 0.020 |
Why?
|
Caloric Restriction | 1 | 2007 | 106 | 0.020 |
Why?
|
Gene Deletion | 1 | 2006 | 67 | 0.020 |
Why?
|
Endotoxins | 1 | 2006 | 37 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2006 | 81 | 0.020 |
Why?
|
Serum Albumin | 1 | 2006 | 54 | 0.020 |
Why?
|
Dietary Proteins | 1 | 2006 | 55 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2006 | 84 | 0.020 |
Why?
|
Energy Intake | 1 | 2006 | 128 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2006 | 247 | 0.020 |
Why?
|
In Situ Nick-End Labeling | 1 | 2005 | 12 | 0.020 |
Why?
|
DNA, Complementary | 1 | 2005 | 30 | 0.020 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2005 | 14 | 0.020 |
Why?
|
Amino Acid Motifs | 1 | 2005 | 24 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2006 | 238 | 0.020 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2005 | 36 | 0.020 |
Why?
|
Ligands | 1 | 2005 | 81 | 0.020 |
Why?
|
Scavenger Receptors, Class A | 1 | 2004 | 6 | 0.020 |
Why?
|
Binding Sites | 1 | 2005 | 130 | 0.020 |
Why?
|
Glutathione Peroxidase | 1 | 2004 | 9 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2006 | 525 | 0.020 |
Why?
|
Biological Availability | 1 | 2004 | 21 | 0.020 |
Why?
|
Lipid Peroxidation | 1 | 2004 | 33 | 0.020 |
Why?
|
Diabetic Nephropathies | 1 | 2006 | 224 | 0.010 |
Why?
|
Liver | 1 | 2007 | 484 | 0.010 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 14 | 0.010 |
Why?
|
Thioredoxins | 1 | 2002 | 21 | 0.010 |
Why?
|
Cattle | 1 | 2002 | 103 | 0.010 |
Why?
|
Apolipoproteins | 1 | 2004 | 200 | 0.010 |
Why?
|
Stress, Mechanical | 1 | 2002 | 92 | 0.010 |
Why?
|
Dactinomycin | 2 | 1991 | 10 | 0.010 |
Why?
|
Aging | 1 | 2007 | 947 | 0.010 |
Why?
|
Cycloheximide | 1 | 1991 | 9 | 0.010 |
Why?
|
Arachidonic Acid | 1 | 1991 | 35 | 0.010 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 1991 | 31 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1991 | 170 | 0.010 |
Why?
|
Diglycerides | 1 | 1990 | 4 | 0.010 |
Why?
|
Phospholipases A2 | 1 | 1990 | 20 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 1991 | 261 | 0.010 |
Why?
|